Patents by Inventor Charlotte Emig
Charlotte Emig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9173927Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.Type: GrantFiled: August 1, 2014Date of Patent: November 3, 2015Assignee: STEMNION, INC.Inventors: Charlotte A Emig, Catherine J Trumpower, George L Sing
-
Publication number: 20150202235Abstract: The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies.Type: ApplicationFiled: November 20, 2014Publication date: July 23, 2015Applicant: Stemnion, Inc.Inventors: Charlotte A. Emig, Vivienne S. Marshall
-
Publication number: 20150050251Abstract: The invention is directed to methods for the treatment of wounds. Such methods utilize novel compositions, including but not limited to amnion-derived multipotent cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine suspension or ACCS), cell lysates derived therefrom, cell products derived therefrom, each alone or in combination.Type: ApplicationFiled: October 23, 2014Publication date: February 19, 2015Inventors: Catherine J Trumpower, Charlotte A. Emig
-
Publication number: 20150025007Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.Type: ApplicationFiled: August 1, 2014Publication date: January 22, 2015Inventors: Charlotte A. Emig, Catherine J. Trumpower, George L. Sing
-
Patent number: 8877181Abstract: The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies.Type: GrantFiled: October 3, 2012Date of Patent: November 4, 2014Assignee: Stemnion, Inc.Inventors: Charlotte Emig, Vivienne S Marshall, Richard A Banas
-
Patent number: 8871198Abstract: The invention is directed to methods for the treatment of wounds. Such methods utilize novel compositions, including but not limited to amnion-derived multipotent cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine suspension or ACCS), cell lysates derived therefrom, cell products derived therefrom, each alone or in combination.Type: GrantFiled: March 14, 2007Date of Patent: October 28, 2014Assignee: Stemnion, Inc.Inventors: Charlotte A Emig, Catherine J Trumpower, Vivienne S Marshall
-
Patent number: 8808753Abstract: The invention is directed to methods for treating pustular conditions of the skin, for example, acne. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), cell lysates derived therefrom, and cell products derived therefrom, each alone or in combination.Type: GrantFiled: March 6, 2013Date of Patent: August 19, 2014Assignee: Stemnion, Inc.Inventors: Linda O Palladino, Vivienne S Marshall, Charlotte A Emig
-
Patent number: 8796025Abstract: The invention is directed to methods for the treatment of wounds. Such methods utilize novel compositions, including but not limited to amnion-derived multipotent cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine suspension or ACCS), cell lysates derived therefrom, cell products derived therefrom, each alone or in combination.Type: GrantFiled: May 8, 2012Date of Patent: August 5, 2014Assignee: Stemnion, Inc.Inventors: Charlotte A Emig, Catherine J Trumpower, Vivienne S Marshall
-
Patent number: 8741646Abstract: The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies.Type: GrantFiled: October 6, 2011Date of Patent: June 3, 2014Assignee: Stemnion, Inc.Inventors: Charlotte A Emig, Vivienne S Marshall
-
Patent number: 8709402Abstract: The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies.Type: GrantFiled: October 3, 2012Date of Patent: April 29, 2014Assignee: Stemnion, Inc.Inventors: Charlotte Emig, Vivienne S Marshall
-
Patent number: 8685390Abstract: The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies.Type: GrantFiled: October 3, 2012Date of Patent: April 1, 2014Assignee: Stemnion, Inc.Inventors: Charlotte Emig, Vivienne S. Marshall
-
Patent number: 8530418Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.Type: GrantFiled: October 17, 2012Date of Patent: September 10, 2013Assignee: Stemnion, Inc.Inventors: Vivienne S Marshall, Catherine J Trumpower, Charlotte Emig
-
Publication number: 20130115197Abstract: The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies.Type: ApplicationFiled: October 3, 2012Publication date: May 9, 2013Applicant: STEMNION, INC.Inventors: Charlotte Emig, Catherine J. Trumpower, Vivienne S. Marshall